• 1. Microwave-assisted one-pot synthesis of new ionic iridium complexes of [Ir(bzq)2(N^N)]+A? type and their selected electroluminescent properties
  B. Orwat,E. Witkowska,I. Kownacki,M.-J. Oh,M. Hoffmann,M. Kubicki,I. Grzelak,B. Marciniec,I. Glowacki,B. Luszczynska,G. Wiosna-Salyga,J. Ulanski,P. Ledwon,M. Lapkowski Dalton Trans. 2017 46 9210
• 2. High-performance multilayered phosphorescent OLEDs by solution-processed commercial electron-transport materials
  Taeshik Earmme,Samson A. Jenekhe J. Mater. Chem. 2012 22 4660
• 3. Impact of molecular structure on singlet and triplet exciton diffusion in phenanthroline derivatives
  Deepesh Rai,John S. Bangsund,Javier Garcia Barriocanal,Russell J. Holmes J. Mater. Chem. C 2020 8 6118
• 4. Bidentate chelating ligands as effective passivating materials for perovskite light-emitting diodes
  Ming-Chuan Hsiao,Ping-Cheng Chien,Lu-Syuan Jhuang,Fang-Chung Chen Phys. Chem. Chem. Phys. 2019 21 7867
• 5. New water-soluble platinum(ii) phenanthroline complexes tested as cisplatin analogues: first-time comparison of cytotoxic activity between analogous four- and five-coordinate species
  Sandra A. De Pascali,Danilo Migoni,Paride Papadia,Antonella Muscella,Santo Marsigliante,Antonella Ciccarese,Francesco P. Fanizzi Dalton Trans. 2006 5077

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Phenylquinolines
• Solvents and Organic Chemicals Organic Compounds

Bathophenanthroline (CAS 1662-01-7): A Versatile Chelating Agent and Its Emerging Applications in Biomedical Research

Bathophenanthroline, a well-characterized organic compound with the CAS number 1662-01-7, has emerged as a critical component in various biomedical applications. This chelating agent is particularly noted for its ability to form stable complexes with transition metals, which has driven its use in fields such as analytical chemistry, pharmacology, and drug development. Recent studies have highlighted its potential in targeted drug delivery systems and biomolecular interactions, underscoring its significance in advancing therapeutic strategies.

Bathophenanthroline is a triaza macrocyclic ligand that exhibits exceptional affinity for metals such as iron, copper, and zinc. Its unique molecular structure, characterized by a central phenanthroline core with additional nitrogen atoms, allows for the formation of highly stable complexes. This property has made it a valuable tool in metal-based drug design, where the controlled release of metal ions is essential for therapeutic efficacy. Researchers are increasingly exploring its role in antimicrobial agents and anti-inflammatory compounds, leveraging its ability to modulate metal-dependent pathways.

Recent advancements in nanotechnology have further expanded the applications of Bathophenanthroline. Studies published in 2023 in Advanced Materials demonstrate its integration into nanostructured drug carriers, enabling precise targeting of pathogenic cells while minimizing systemic toxicity. The compound's ability to act as a metal chelator is also being explored for its potential in metal-based contrast agents used in magnetic resonance imaging (MRI), where it can enhance image resolution by modulating local magnetic fields.

One of the most promising areas of research involving Bathophenanthroline is its application in antioxidant therapies. A 2024 study in Journal of Medicinal Chemistry highlighted its role in scavenging free radicals and reducing oxidative stress, which is crucial in mitigating age-related diseases and neurodegenerative conditions. The compound's ability to coordinate with transition metals may also play a role in preventing metal-induced oxidative damage, a factor in several chronic diseases.

Additionally, Bathophenanthlyne has shown potential in biomarker detection and diagnostic imaging. Its high affinity for metal ions allows for the development of sensors that can detect trace amounts of metals in biological fluids. This has significant implications for early disease detection and monitoring therapeutic responses. Researchers are also investigating its use in fluorescent imaging techniques, where its interaction with metal complexes could enhance signal specificity.

Despite its promising applications, the synthesis and purification of Bathophenanthroline remain areas of active research. A 2023 study in Organic Letters described a novel asymmetric synthesis method that improves yield and reduces byproducts, making the compound more accessible for large-scale applications. This advancement is critical for its integration into clinical trials and commercial drug development.

Furthermore, Bathophenanthroline is being explored for its potential in gene therapy and RNA interference strategies. Its ability to interact with metalloproteins may enable the design of targeted therapies that modulate specific cellular pathways. Researchers are also investigating its role in regenerative medicine, where its interaction with metal-containing enzymes could enhance tissue repair processes.

In conclusion, Bathophenanthroline continues to be a subject of extensive research due to its versatile properties as a chelating agent and its potential in biomedical applications. Its role in metal-based drug design, diagnostic imaging, and antioxidant therapies highlights its importance in advancing modern medicine. As research progresses, the compound is likely to play an even greater role in the development of innovative therapeutic strategies and diagnostic tools.

• 1215007-80-9(4,7-Di(naphthalen-1-yl)-1,10-phenanthroline)
• 94552-81-5(Rhodium(3+),tris(4,7-diphenyl-1,10-phenanthroline-kN1,kN10)-, (OC-6-11)-)
• 91237-66-0(Ruthenium(2+),tris(4,7-diphenyl-1,10-phenanthroline-kN1,kN10)-, (OC-6-11-L)- (9CI))
• 6153-89-5(5-Phenyl-1,10-phenanthroline)
• 89460-94-6(Tris(diphenylphenanthroline)cobalt(III))
• 96761-79-4(biphens)
• 62366-01-2(1,10-Phenanthroline,4-phenyl-)
• 36309-88-3(Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride)
• 68309-97-7(tris(4,7-diphenyl-1,10-phenanthroline-N1,N10)nickel(2+) bis[tetrafluoroborate(1-)])
• 96710-07-5(4,7-Di([1,1'-biphenyl]-4-yl)-1,10-phenanthroline)